An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery
成果类型:
Article
署名作者:
Huang, Qin; Chan, Ken Y.; Wu, Jason; Botticello-Romero, Nuria R.; Zheng, Qingxia; Lou, Shan; Keyes, Casey; Svanbergsson, Alexander; Johnston, Jencilin; Mills, Allan; Lin, Chin-Yen; Brauer, Pamela P.; Clouse, Gabrielle; Pacouret, Simon; Harvey, John W.; Beddow, Thomas; Hurley, Jenna K.; Tobey, Isabelle G.; Powell, Megan; Chen, Albert T.; Barry, Andrew J.; Eid, Fatma-Elzahraa; Chan, Yujia A.; Deverman, Benjamin E.
署名单位:
Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Egyptian Knowledge Bank (EKB); Al Azhar University
刊物名称:
SCIENCE
ISSN/ISSBN:
0036-12454
DOI:
10.1126/science.adm8386
发表日期:
2024-06-14
页码:
1220-1227
关键词:
adenoassociated virus
pabinafusp alpha
barrier
therapy
transcytosis
antibody
vectors
iduronate-2-sulfatase
TRAFFICKING
dementia
摘要:
Developing vehicles that efficiently deliver genes throughout the human central nervous system (CNS) will broaden the range of treatable genetic diseases. We engineered an adeno-associated virus (AAV) capsid, BI-hTFR1, that binds human transferrin receptor (TfR1), a protein expressed on the blood-brain barrier. BI-hTFR1 was actively transported across human brain endothelial cells and, relative to AAV9, provided 40 to 50 times greater reporter expression in the CNS of human TFRC knockin mice. The enhanced tropism was CNS-specific and absent in wild-type mice. When used to deliver GBA1, mutations of which cause Gaucher disease and are linked to Parkinson's disease, BI-hTFR1 substantially increased brain and cerebrospinal fluid glucocerebrosidase activity compared with AAV9. These findings establish BI-hTFR1 as a potential vector for human CNS gene therapy.